Ridgetech Inc. (RDGT) - Form 20-F Summary
Business Context and Reporting Period
Company: Ridgetech Inc. (formerly China Jo-Jo Drugstores, Inc.)
Reporting Period: Fiscal year ended March 31, 2026
Jurisdiction: Cayman Islands (Operations primarily in PRC)
Business Model: Following a major restructuring in February 2025, the Company divested its retail pharmacy business (Jiuxin Investment) and acquired Ridgeline International Limited (parent of Allright). The Company now operates exclusively as a wholesale distributor of pharmaceutical and healthcare products through two segments: offline wholesale and online platform sales.
Key Financial Metrics (Fiscal Year Ended March 31, 2026)
| Metric | 2026 | 2025 | Change |
|---|---|---|---|
| Total Revenue | $132.16 million | $119.97 million | +10.2% |
| Gross Profit | $4.75 million | $3.84 million | +23.8% |
| Gross Margin | 3.6% | 3.2% | +0.4 pts |
| Operating Loss | $(1.87) million | $(1.04) million | -80.2% |
| Net Loss (Continuing Ops) | $(1.25) million | $(1.45) million | +13.7% |
| Cash & Equivalents | $17.91 million | $18.54 million | -3.4% |
| Working Capital | $36.66 million | $25.35 million | +44.6% |
| Notes Payable | $22,669 | $10.39 million | -99.8% |
Note: 2025 results included a one-time gain of $15.76 million from the divestiture of Jiuxin Investment, resulting in a reported Net Income of $10.20 million for that year. 2026 results reflect only continuing operations.
Material Changes vs. Prior Period
- Strategic Restructuring: Completed divestiture of retail operations (Jiuxin Investment) and acquisition of Allright (online/offline wholesale) in February 2025. Retail operations are now reported as discontinued.
- Revenue Composition: Offline wholesale revenue decreased slightly ($117.87M vs $118.86M) due to the discontinuation of credit sales to mitigate risk. Online platform revenue surged 1,190.8% ($14.29M vs $1.11M) due to the inclusion of a full year of Allright's operations.
- Customer Concentration: Following the divestiture, sales to the former retail entity (Jiuzhou Pharmacy) are now treated as third-party sales. One customer accounted for 53.7% of total revenue in 2026, compared to two customers accounting for 85.8% in 2025.
- Debt Reduction: Notes payable decreased from $10.39 million to $22,669, significantly reducing interest obligations and improving liquidity.
- Capital Structure: A 1-for-150 reverse share split was effected on April 7, 2026. All share data in this filing is retroactively adjusted.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary & Outlook: Management believes the Company has sufficient resources to support operations for the next 12 months. The focus remains on expanding the wholesale business through the Allright acquisition and maintaining the supply relationship with Jiuzhou Pharmacy under a three-year agreement. The Company is actively pursuing capital raising via an At-The-Market (ATM) program.
Material Risks:
- Customer Concentration: Over 50% of revenue relies on a single customer (Jiuzhou Pharmacy). Termination of the supply agreement would materially impact results.
- Delisting Risk: The Company's Market Value of Listed Securities (MVLS) is currently below the $5.0 million Nasdaq requirement. Failure to maintain this for 30 consecutive days could trigger immediate suspension and delisting.
- Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of March 31, 2026, due to material weaknesses including lack of timely reconciliation from China GAAP to U.S. GAAP and insufficient accounting staff experience.
- Regulatory Environment: Significant risks related to PRC regulations, data security laws, and the Holding Foreign Companies Accountable Act (HFCAA) regarding PCAOB inspections.
Unusual Items:
- Preferred Shares Issuance: On July 16, 2026, the Company issued 100,000 Series A Preferred Shares to Chairman Lingtao Kong for $100. These shares carry 100 votes per share, giving the Chairman approximately 73.5% of total voting power.
- ATM Program: As of the report date, the Company had sold 3.49 million shares under its ATM program for gross proceeds of $15.28 million.
Investor Verification Checklist
- Verify MVLS Status: Confirm current Market Value of Listed Securities to assess immediate delisting risk under new Nasdaq rules.
- Review Internal Control Remediation: Assess the progress of remediation for the identified material weaknesses in financial reporting.
- Monitor Supply Agreement: Track the stability of the supply relationship with Jiuzhou Pharmacy, which accounts for >50% of revenue.
- Check Voting Rights: Understand the implications of the Series A Preferred Shares issued to the Chairman on corporate governance and minority shareholder rights.
- Assess Liquidity: Verify the availability of the $5.79 million bank credit line and the sustainability of cash flows given the operating loss.